Method of soft tissue augmentation
AssigneePalette Life Sciences AB
InventorBengt Agerup
Life of this patent
Estimating the term…
Abstract
Particles made of a viscoelastic medium, are injectable gel particles, and have a size, when subjected to a physiological salt solution, in the range of from 1 to 5 mm. The particles are useful in a soft tissue augmentation implant. The implant includes particles of a viscoelastic medium, wherein a major volume of the particles are injectable gel particles The implant is useful in a method of soft tissue augmentation in a mammal, including man, comprising subepidermal administration at a site in said mammal where soft tissue augmentation is desirable, of an implant.
Claims20
A composition comprising particles of a viscoelastic medium comprising stabilized hyaluronic acid,
- wherein said particles are injectable gel particles suitable for implantation having a size,
- when subjected to a physiological salt solution, in the range of from 1.5 to 5 mm, wherein said physiological salt solution has the same osmolarity as a 0.154 M NaCl solution;
- wherein said viscoelastic medium comprises cross-linked hyaluronic acid.
A soft tissue augmentation implant comprising particles of a viscoelastic medium comprising stabilized hyaluronic acid,
- wherein a major volume of said particles are injectable gel particles having a size, when
- subjected to a physiological salt solution, in the range of from 1.5 to 5 mm;
- wherein said viscoelastic medium is selected from the group consisting of cross-linked hyaluronic acid;
- wherein said physiological salt solution has the same osmolarity as a 0.154 M NaCl solution.
A method of diminishing migration or displacement of an implant, comprising administering subepidermal by injection a volume of 1 to 10 ml of a viscoelastic medium through a 18 to 20 gauge needle by application of a pressure of about 15 N to about 40 N at a site of said human subject, wherein the viscoelastic medium comprises gel particles comprising cross-linked hyaluronic acid and derivatives thereof, wherein the concentration of said cross-linked hyaluronic acid and derivatives thereof in said gel particles, when subjected to a physiological salt solution, is in the range of from 12 to 23 mg/ml, and wherein at least 50% (v/v) of said gel particles has a size range, when subjected to the physiological salt solution, in the range of from 3 to 4 mm, wherein the hyaluronic acid is cross-linked with 1,4-butanediol diglycidyl ether, whereby migration or displacement of the gel particles from the administration site is prevented or decreased.
Dependencies are inferred from the claim text.